Printer Friendly

AMGEN WINS EPO PATENT INTERFERENCE

 AMGEN WINS EPO PATENT INTERFERENCE
 THOUSAND OAKS, Calif., Dec. 5 /PRNewswire/-- Amgen Inc.


(NASDAQ-NMS: AMGN) today confirmed that The Board of Patent Appeals and Interferences of the United States Patent and Trademark Office has rendered judgement in favor of Amgen in each of the three interferences regarding recombinant human erythropoietin.
 The first interference dealt with the previously issued patent awarded to Amgen's Dr. Fu-Kuen Lin, U.S. Patent number 4,703,008. The claims of this patent include the DNA, vectors, and host cells required to produce recombinant human erythropoietin.
 The second and third interferences involved two other Amgen patent applications, one of which claims the process to produce recombinant human erythropoietin, and the second of which claims the recombinant human erythropoietin product itself.
 As a result of these decisions, Amgen expects to receive patents for the process to produce recombinant human erythropoietin and the product itself. These patents will strengthen Amgen's patent portfolio protecting its EPOGEN (R) product.
 Amgen is a global pharmaceutical company developing human therapeutic products based on advances in cellular and molecular biology. The company is headquartered in Thousand Oaks.
 -0- 12/5/91
 /CONTACT: Mark J. Brand, director, corporate communications, 805-499-5725, ext. 3028, or Lowell E. Sears, VP, Finance, 805-499- 5725 ext. 3055, both of Amgen/
 (AMGN)


CH -- LA030 -- 9870 12/05/91 17:20 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 5, 1991
Words:221
Previous Article:BELDING HEMINWAY NAMES ASSISTANT VICE PRESIDENTS
Next Article:SIERRA REAL ESTATE EQUITY TRUST '84 ELECTION SURPRISES INCUMBENT DIRECTORS; BALLOTS TO BE INSPECTED
Topics:


Related Articles
MAJOR RIBOZYME PATENT GRANTED IN EUROPE
Transkaryotic prevails over Kirin-Amgen in House of Lords Dynepo litigation.
Amgen files with ITC against Roche against Roche's importation of peg-EPO; Roche will still seek US approval.
Appeals Court affirms patent infringement rulings against Roche's peg-EPO product.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters